Events & Conferences

How to make latest cancer therapies also available for children

How adult drugs from the group of MAP kinase inhibitors can also be used in children with cancer in a standardized manner worldwide has now been outlined in a statement in the renowned European Journal of Cancer. The authors of this review are stakeholders from all relevant fields, including Caroline Hutter, MD, PhD, scientist at St. Anna Children's Cancer Research Institute, clinician at St. Anna Children's Hospital and expert in the rare pediatric cancer Langerhans cell histiocytosis (LCH). Her goal is to test the most effective and tolerable MAP kinase inhibitor in a clinical trial, thus enabling rapid market approval and availability for children.

New FWF project for Davide Seruggia and Ana Kutschat to decode risk factors for childhood leukemia 

On hot track! Davide Seruggia and Ana Kutschat focus on new epigenetic factors associated with risk of developing childhood leukemia.

St. Anna CCRI attends “Better Medicines for Children Conference 2022”

Four ÖGKJ prizes for St. Anna Children’s Cancer Research Institute and St. Anna Children’s Hospital

This year, all three prizes, as well as the "best abstract of the conference" go to St. Anna Children's Cancer Research Institute (St. Anna CCRI) and St. Anna Children's Hospital!

…and the ÖGMBT Best Talk Award goes to: Eva König!

…and the ÖGMBT Best Talk Award goes to: Eva König!

Networking with young talents: St. Anna Children’s Cancer Research Institute goes Life Science Career Fair 2022

Socializing, getting further education and screening job offers: This year's Life Science Career Fair of the ÖGMBT offered a wide range of opportunities for students and graduates.

Eva König wins Heribert-Konzett-Prize!

A great success! Dr. Eva König, principal investigator at St. Anna CCRI, is honored with the Heribert-Konzett-Prize of the Austrian Pharmacological Society (APHAR) for her scientific work on the interaction between immune and cancer cells. The prize is awarded to recognize the achievements of young scientists already conducting independent research in the field of experimental and clinical pharmacology and to encourage their further development.

Evolution 2.0: What makes cancer more malignant

St. Anna CCRI epigenetics researcher Peter Peneder wins ÖGMBT-award!

Nerve healing: neighboring cells become police force – and could make tumors benign

Florian Halbritter: “Be open and curious, listen, learn, adapt, and improve.”

Scientists off the record: In our summer interview series, St. Anna Children's Cancer Researcher Florian Halbritter shares not only his summer reading shortlist, but also his best advice to bring forward great ideas.

Childhood Leukemia treatment 2022: where we are now and what it takes

Pediatric cancer researchers publish collection of leukemia reviews in top journal “Frontiers in Pediatrics”. According to the authors, new therapies could spare some children a stem cell transplantation.

Gold and Brave against Childhood Cancer

September is Childhood Cancer Awareness Month – a month dedicated to remind us of the dire need to find more and better cures for this devastating disease.

Scientists off the record: “… coincidentally stumbled upon leukemia cells”

St. Anna Childhood Cancer Researcher Michael Dworzak explains which question drives him, what matters in research/life and how to keep cool on hot summer days.

Scientist Sabine Taschner-Mandl off the record: “Be bold and brave – and think outside the box!”

St. Anna Children’s Cancer Researcher Sabine Taschner-Mandl strives to improve the treatment of childhood nerve tumors. We asked what arouses her curiosity and how she spends her summer holidays.

Two St. Anna CCRI projects selected for FWF’s 1000 ideas program

This year’s 1000 ideas program of FWF promotes another two of St. Anna CCRI’s “completely new, daring or particularly original research ideas that lie outside the current scientific understanding”. Florian Halbritter’s new approach aims to integrate machine learning directly into the experimental design and execution of manufacturing specific cell types from stem cells – with the ultimate goal to reprogram even cancer cells. Artem Kalinichenko, who was also awarded a 1000 ideas grant, is targeting abnormal tumor metabolism by identifying cancer-derived metabolites, drugs and drug metabolites that trigger an immune reaction, which could later be exploited for immunotherapy.